Skip to main content

Dako to Develop Cancer Companion Dx for Bristol-Myers Squibb

NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with drug maker Bristol-Myers Squibb to develop clinical diagnostics as companions to cancer therapeutics.
 
The Danish diagnostics firm plans to develop clinical diagnostics that can identify cancer patients who may benefit from drug candidates that Bristol-Myers Squibb has in development.
 
Dako CEO Patrick Dahlen said the tests it develops under the collaboration will be companion products for specific Bristol-Myers Squibb therapeutics.
 
Further terms of the agreement were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.